Experience

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1 billion aggregate principal amount of its 3.150% senior notes due 2020 and (ii) $1 billion aggregate…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $300 million aggregate principal amount of its floating-rate senior notes…

Davis Polk advised the representatives of the underwriters in connection with the $175.5 million offering of 2,700,000 shares of common stock of REGENXBIO Inc. The common stock is listed on…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1.6 billion aggregate principal amount of its 3.500% senior notes due 2023 and (ii) $400 million…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $500 million aggregate principal amount of its 3.000% senior notes due 2020, (ii) $900 million…

Davis Polk advised the joint book-running managers in connection with the $172 million public offering of common stock of Deciphera Pharmaceuticals, Inc. The common stock is listed on…

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant Pharmaceuticals…

Davis Polk advised the Province of New Brunswick in connection with the offering of $500 million aggregate principal amount of 3.625% bonds due February 24, 2028. The Davis Polk team…

Davis Polk advised the underwriter in connection with the $56.6 million secondary offering of 2,200,000 shares of common stock of TriState Capital Holdings, Inc. by selling…

Davis Polk advised MSCI Inc. in connection with a Rule 144A/Regulation S offering of $500 million aggregate principal amount of its 5.375% senior notes due 2027 and a concurrent amendment…